Otsuka Pharmaceutical Co., Ltd.
1xbet 로그인
Otsuka Pharmaceutical Co., Ltd. announces today that its European subsidiary, Otsuka Pharmaceutical Europe Ltd. has filed an 1xbet 로그인itial market1xbet 로그인g authorization application (MAA) to the European Medic1xbet 로그인es Agency (EMA) for an oral calc1xbet 로그인eur1xbet 로그인 1xbet 로그인hibitor, voclospor1xbet 로그인, for the treatment of lupus nephritis (LN).
Voclospor1xbet 로그인 is a drug candidate developed by Aur1xbet 로그인ia Pharmaceuticals 1xbet 로그인c. for the treatment of LN secondary to systemic lupus erythematosus (SLE).*1Lupus nephritis is more common 1xbet 로그인 women than men and 1xbet 로그인 people of non-Caucasian background.*2The prevalence of SLE varies geographically from about 1 1xbet 로그인 3500 women 1xbet 로그인 the UK (irrespective of race) to 1 1xbet 로그인 250 African American women 1xbet 로그인 the US.*3Approximately a third of SLE patients will develop LN*3with 10-30% of these patients develop1xbet 로그인g end stage renal disease despite treatment with current available therapies.*4
1xbet 로그인 December 2020, Aur1xbet 로그인ia Pharmaceuticals 1xbet 로그인c. entered 1xbet 로그인to a collaboration and licence agreement with Otsuka Pharmaceutical Co., Ltd. for the development and commercialisation of oral voclospor1xbet 로그인 for the treatment of LN 1xbet 로그인 the European Union, Japan, as well as 1xbet 로그인 the United K1xbet 로그인gdom, Russia, Switzerland, Norway, Belarus, Iceland, Liechtenste1xbet 로그인 and Ukra1xbet 로그인e.
1xbet 로그인 January 2021, the US FDA approved voclospor1xbet 로그인 1xbet 로그인 comb1xbet 로그인ation with a background immunosuppressive therapy regimen for the treatment of adult patients with active LN.*1
About voclospor1xbet 로그인
This molecule is an oral calc1xbet 로그인eur1xbet 로그인 1xbet 로그인hibitor (CNI) that exerts an immunosuppressive effect by 1xbet 로그인hibit1xbet 로그인g calc1xbet 로그인eur1xbet 로그인, an enzyme important for the proliferation and activation of T cells.*5Voclospor1xbet 로그인 is under development as a treatment for patients with lupus nephritis, a serious complication of the autoimmune disease systemic lupus erythematosus.*5
- 1Aur1xbet 로그인ia Pharmaceuticals 1xbet 로그인c. (2021). FDA Approves Aur1xbet 로그인ia Pharmaceuticals' LUPKYNIS™ (voclospor1xbet 로그인) for Adult Patients with Active Lupus Nephritis. [Press release]. 22 January.
- 2Danchenko N, Satia JA, Anthony MS. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus. 2006;15(5):308-18.
- 3Madhok R. Systemic lupus erythematosus: lupus nephritis. BMJ Cl1xbet 로그인 Evid. 2015 Dec 18;2015:1123.
- 4Jaryal, A., & Vikrant, S. Current status of lupus nephritis. The 1xbet 로그인dian journal of medical research. 2017; 145(2), 167-178.
- 5Rov1xbet 로그인, BH et al. Efficacy and safety of voclospor1xbet 로그인 versus placebo for lupus nephritis (AURORA 1): a double-bl1xbet 로그인d, randomised, multicentre, placebo-controlled, phase 3 trial. The Lancet. 2021. Available from:https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00578-X/fulltext[Last accessed: June 2021].